[ TRANSACTION RECORD ]

Goldman Sachs Asset Management Investment in Seagen — 2023

VERIFIED VECTOR ID: 001562 · tx-090
M SOURCE NODE — FUNDER
Goldman Sachs Asset Management
Finance United States
$43,000,000,000
EQUITY
14/12/2023
Q DESTINATION NODE — RECIPIENT
Seagen
Company United States
Amount (USD)
$43.0B
Flow Type
EQUITY
Transaction Date
14/12/2023
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity Goldman Sachs Asset Management
AUM 2800000
HQ Location United States
Sector Finance
Recipient Profile [ Q ]
Entity Seagen
Entity Type Company
Jurisdiction United States
Intelligence Note

Pfizer Inc. finalized the 43 billion dollar acquisition of Seagen to establish a world-class oncology organization focused on antibody-drug conjugates. The transaction is one of the largest in biotech history, significantly expanding Pfizer’s cancer treatment capabilities. This deal represents a massive deployment of institutional capital into the advancement of oncology medicine.

Σ
Primary Forensic Source https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen/
✓ SOURCE LINKED